PDA Next Generation Sequencing Workshop 2024
Registration Options
Individual Registration
Group Registration
Program Highlights
The agenda preview is now published!
Join this one-day interactive workshop after the PDA Virus Conference 2024, and join the discussion with industry experts on challenges and solutions all around NGS!
Dear Colleague,
We would like to invite you to the PDA Next Generation Sequencing Workshop 2024 to take place on 28 June 2024 in Amsterdam, The Netherlands directly after the PDA Virus Conference 2024.
We look forward to welcoming you!
Sincerely,
The Workshop Leader
Simone Olgiati, Merck KGaA
SCIENTIFIC PROGRAM PLANNING COMMITTEE
- Simone Olgiati, Merck KGaA
- Alison Armstrong, Merck KGaA
- Andy Bailey, ViruSure
- Johannes Bluemel, Paul-Ehrlich-Institut
- Arifa Khan, U.S. FDA
- Sean O'Donnell, Eli Lilly and Company
- Sebastian Teitz, Biopharma Excellence
- Falk Klar, PDA Europe
- Stefanie Nebelin, Senior Manager Programs & Events, PDA Europe
Event Location
Contact
Program Inquiries
Exhibition/Sponsorship Inquiries
Training Course Inquiries
Registration Customer Care
Standard Registration
Member Price
€1.080Non-Member
€1.080
ALL PRICES IN EURO (EUR), EXCLUDING VAT.
WAYS TO REGISTER: 1. Online Registration 2. [email protected]
PDA MEMBERS: Please remember to log in before registering If you come from a Governmental or Health Authority Institution or from an Academic Organization, please contact [email protected] before registering.
If you need to apply for a visa to enter the event country, PDA Europe must be informed of this fact at least 4 weeks before the start of the event.
Day 1
Friday, 28 June 2024
| 09:00 Welcome and Introduction |
|---|
Falk Klar, PDA |
| Topic 1: Implementation of Next Generation Sequencing in a Regulated Environment |
|---|
Moderator: Controls and Reference Standards for Next Generation Sequencing Pharmacopoeia Chapter 2.6.41 on High Throughput Sequencing EFPIA’s Perspective on Validation of Next Generation Sequencing for Virus Safety Testing |
10:00 - 10:30 Coffee Break
| Cont. Topic 1: Implementation of Next Generation Sequencing in a Regulated Environment | |||||
|---|---|---|---|---|---|
| Update on FDA perspective on NGS for Virus Detection Arifa Khan, U.S. FDA Round Table Discussion Hot Topics and Open Questions Moderators: Andy Bailey, ViruSure Simone Olgiati, Merck
12:00 - 13:00 Lunch Break
|
Featured Presenters
-
Melissa Alzona, PhD
Merck
Read Bio
Melissa Alzona, PhD
Merck
Melissa Alzona, PhD, is Associate Scientist in the Innovative Sequencing laboratory at Merck. In her role, she is actively involved in development of molecular-based methods using cutting edge sequencing technologies, with a particular focus on virus detection strategies. She holds a Master Degree in Molecular Biology from the University of Turin and a PhD in Molecular Medicine in collaboration with Merck. During her studies she focused on innovative molecular methods to support Quality Control and to improve the Cell Line Development process, developing strong expertise on both the Droplet Digital PCR and Next Generation Sequencing technologies
-
Elodie Charbaut Taland, PhD
Global Regulatory Affairs, Merck
Read Bio
Elodie Charbaut Taland, PhD
Merck
Elodie Charbaut Taland works as Associate Director in Merck KGaA GRA CMC Regulatory Intelligence team. She has 15 years of experience in biological drug substance process development and manufacturing, covering development products, marketed products, and biosimilars. She is now involved in CMC regulatory intelligence activities, with a focus on advocacy for the introduction of innovative technologies. In this context, she is co-leading the elaboration of the EFPIA position paper on the use of Next Generation Sequencing for virus safety testing. Elodie Charbaut Taland holds an Engineering degree from Ecole Polytechnique, France, and a PhD in Neurosciences from the University Pierre et Marie Curie, France.
-
Izabela Fabianska
IDT Biologika
Read Bio
Izabela Fabianska
IDT Biologika
Dr. Izabela Fabianska is a scientist in the Analytical Development team at IDT Biologika since 2020, where she performs computational analyses of sequencing data. She was involved in the development and validation of the analysis workflows for virus detection and genome identity testing. She studied biotechnology in Poznan, Poland before she joined the International Max Planck Research School (IMPRS) at the Max Planck Institute for Plant Breeding Research in Cologne, Germany. In 2017, she received a PhD degree from the University of Cologne. During her PhD and short post-doc, she did research in plant and soil microbiome including the plant molecular responses to environmental changes, NGS sample preparation, development of NGS data analysis pipeline, and multivariate data analysis.
-
Hans Peter Fasching
ViruSure
Read Bio
Hans Peter Fasching
ViruSure
He studied molecular biology with a focus on molecular medicine at the University of Vienna. Hans-Peter started at ViruSure in 2015 as a scientific assistant also performing his master thesis within the company. The title of the thesis was “Development of Real-time PCR assays and application of next generation sequencing for viral safety evaluation of insect cell substrates and derived bioproducts”. After finishing his master’s thesis, he continued working at ViruSure and implemented the Sanger Sequencing service. While at the company, he progressed to become both GMP assay coordinator and GLP study director. Currently he is the deputy head of the molecular biology group and focus on the establishment of NGS services.
-
Christophe Lambert, PhD
GSK
Read Bio
Christophe Lambert, PhD
GSK
Christophe Lambert is Associate Director in Data Science at GSK Vaccines in Belgium. He graduated B.Sc. and M.Sc. in Chemistry and was awarded PhD in bioinformatics from the University of Namur (Belgium) in 2003 for the automated prediction of protein 3D structures and for the automated bacterial genome annotation. In 2003, Dr. Lambert co-founded a company providing expert bioinformatics services to pharmaceutical, biotech and agrofood companies. In 2006, he also co-founded BioWin, the Health competitiveness cluster of Wallonia (Belgium), bringing together stakeholders participating in innovative projects and/or education in the fields of Health biotechnology and medical technologies. He joined GSK in 2014 to provide expertise in protein 3D structure, HTS data analysis and manage the development of an analysis pipeline for Adventitious Virus Detection. Since 2016, Dr. Lambert is the leader of the AVDTIG Subgroup D exploring bioinformatics pipelines and reviewing best practices and perspectives about using HTS for virus detection.
-
Siemon Ng, PhD
Notch Therapeutics
Read Bio
Siemon Ng, PhD
Notch Therapeutics
Dr. Siemon Ng is the Senior Director, Analytical Development and Quality at Notch Therapeutics and is responsible for developing and implementing the analytical strategy for Notch’s iPSC-derived immunotherapies.
Dr. Ng has extensive experience with analytical development including next generation sequencing and NGS data analysis, digital PCR, qPCR, and other molecular and immunological techniques. Dr. Ng is an active member of the PDA Advanced Virus Detection Technologies Interest Group and has participated in multiple collaborative studies involving the use of NGS. Prior to joining Notch Therapeutics in 2022, Dr. Ng was the Head of the Molecular Biology Centre at Sanofi Pasteur, Analytical Sciences for vaccine development.
Dr. Ng completed his PhD at Simon Fraser University studying the Atlantic salmon genome. Subsequently, he worked on mouse genomics at The Jackson Laboratory. In 2008, Dr. Ng moved to Toronto to study the genomic landscape of stem cells at the Ontario Institute for Cancer Research and later joined Sanofi Pasteur in 2011.
-
Charles Swofford
MIT
Read Bio
Charles Swofford
MIT
Charley Swofford has been at the Center for Biomedical Innovation at MIT since 2022, where he is the Assistant Director for Biomanufacturing Initiatives. In this role, he manages collaborative sponsored research projects, including investigating ONT sequencing for adventitious agent detection and developing a continuous manufacturing testbed for virus-like particle (VLP) vaccine production. He also supports joint research projects among members of the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB), a pre-competitive biopharmaceutical industry consortium focused on identifying and sharing best practices to mitigate the risk of adventitious agent contamination in biopharmaceutical manufacturing. Dr. Swofford received his Ph.D. in Chemical Engineering from the University of Massachusetts Amherst in 2014, where he engineered microbes for targeted cancer drug delivery.
Sponsorship and Exhibit Opportunities are available!
For more information about exhibit and sponsorship opportunities, please contact:
Christopher Härtig
Senior Manager Exhibition & Sponsorship
Email
Become a Sponsor
Interested in becoming a sponsor? Learn about opportunities and benefits.
Request InformationBecome an Exhibitor
Interested in becoming an exhibitor? Learn about opportunities and benefits.
Request InformationPLEASE READ PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.
Amsterdam Marriott Hotel
Stadhouderskade 12Amsterdam, The Netherlands , The Netherlands
PDA recommends the reservation at the following hotel
Amsterdam Marriott Hotel
Stadhouderskade 12
1054 ES Amsterdam
The
Netherlands
PDA Europe has reserved a limited number of rooms by 11 April 2024.
Book your room at the PDA Group Rate via the above-mentioned reservation button.
How to Get Here
Travel and Exclusive Discount Information
Special Lufthansa Group Airlines Fares
The Lufthansa Group airlines bring people together – every day, all around the world.The global route network of Austrian Airlines, Lufthansa, SWISS, Brussels Airlines and Eurowings offers optimal connection and combination options, so you will benefit from quick and direct flights to the event.
You will reach the booking platform via this link https://www.lufthansa.com/de/en/meetings-and-events-delegates and with the event code DEAPILG. The reduced fares are automatically displayed.
Note: Please enable pop-ups permanently in your browser while booking, otherwise the window in the booking platform will not open.
Of course, you can also book through your IATA travel agency. The travel agency can request the ticketing instructions by sending an email to [email protected], stating the event code DEAPILG.
Book FlightSpecial Deutsche Bahn Train Fares
Get there relaxed – get there sustainable – travel CO2-free. Your Event Ticket at a fixed price throughout Germany. From any Deutsche Bahn station to our event, with the City-Ticket included.
Event Ticket one-way and specific train (subject to availability):
- 1st class 89,90€ (seat reservation incl.)
- 2nd class 55,90€
Event Ticket one-way and fully flexible:
- 1st class 112,90€ (seat reservation incl.)
- 2nd class 77,90€
Book online now and get the lowest price for your preferred route – guaranteed. For technical questions, please contact the service number +49 (0) 30 58 60 20 901. Create the perfect start for your sustainable event: Make active use of your journey to work or just relax and enjoy the high-speed travel experience – with 100% renewable power on regional and long-distance services.
Book TrainArea Attractions
Experience a well-deserved escape at the hotel in Netherlands, Amsterdam. The Amsterdam Marriott Hotel is surrounded by stunning canals and exquisite architecture boasting an unparalleled city centre location across from the Leidseplein, just moments from Amsterdam's iconic attractions. Walk to the Anne Frank House, the Van Gogh Museum, Rijksmuseum and Vondelpark as well as upscale shopping, fine dining and entertainment destinations.